12:00 AM
Mar 24, 2014
 |  BioCentury  |  Finance

Quick turn

How Atlas repackaged Saniona assets and set up an exit path within a year
Quick turn

In less than a year, Atlas has set up a potential exit for Ataxion Inc. via a $17 million tranched series A round that will fund the company through completion of a Phase I study of an undisclosed program. At that point, new investor Biogen Idec Inc. (NASDAQ:BIIB) can exercise an option to acquire the ataxia company.

In addition to participating in...

Read the full 302 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >